



PRODUCT: **Pemazyre® (pemigatinib)**

COMPANY: Incyte

THERAPEUTIC AREA & INDICATION:  
Treatment of cholangiocarcinoma

---

#### ABOUT THE PRODUCT

Pemazyre® (pemigatinib) is a small molecule inhibitor of FGFR 1, 2 and 3 kinases that blocks FGFR phosphorylation and signaling and decreases the viability of cells expressing FGFR gene alterations in preclinical models. Pemazyre is indicated in the U.S. for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. It is the first and only FDA-approved, individualized treatment option for these patients.